United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total value of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total value of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total value of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00.

United Therapeutics Stock Performance

Shares of UTHR traded down $1.33 during mid-day trading on Tuesday, reaching $437.33. 601,802 shares of the company were exchanged, compared to its average volume of 598,006. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $479.50. The stock has a market capitalization of $18.83 billion, a PE ratio of 16.57, a PEG ratio of 4.96 and a beta of 0.66. The business has a 50 day simple moving average of $412.73 and a two-hundred day simple moving average of $339.81.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the company earned $6.39 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank purchased a new position in United Therapeutics in the second quarter worth $136,453,000. Invesco Ltd. lifted its position in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the last quarter. Nuveen LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at $83,533,000. Finally, Amundi lifted its position in shares of United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock valued at $107,635,000 after buying an additional 232,988 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada lifted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $501.90.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.